{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Musabyimana V"],"funding":["National Institute for Health Research (NIHR)","Wellcome Trust","UK Foreign Commonwealth & Development Office","National Institute for Health Research (NIHR) Global Health Research Group award"],"pagination":["106"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12945176"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(2)"],"pubmed_abstract":["Antivenom administration is currently the only therapy for snakebite envenoming. However, in sub-Saharan Africa, inadequate quality control systems have led to deficits in the availability, accessibility, efficacy and safety of regionally available antivenoms, which, in turn, hinder snakebite treatment and management in the region. To address this impediment to snakebite treatment in Kenya, this study aimed to assess the preclinical neutralising potencies of four different antivenoms previously or currently available in Kenya (SAIMR polyvalent, AFRIVEN, PANAF-Premium<sup>TM</sup> and Inoserp<sup>TM</sup>) against key snakes of medical importance in the region, towards establishing a national antivenom quality control laboratory. Venoms were extracted from the Kenyan \"big five\" medically im"],"journal":["Toxins"],"pubmed_title":["Establishing the Kenya National Antivenom Quality Control Laboratory: Preclinical Efficacy Results of Four Antivenoms Against Venoms from the \"Big Five\" Snake Species in Kenya."],"pmcid":["PMC12945176"],"funding_grant_id":["16/137/11","223619/Z/21/Z","16/137/114","#223619/Z/21/Z","#300341-115"],"pubmed_authors":["Casewell NR","Oluoch GO","Musau BM","Khasandi PM","Harrison RA","Thomas BC","Ngugi CW","Ogopotse W","Lubuya J","Adino E","Mwethera PG","Musabyimana V","Kagira JM","Maranga G","Kotti D","Modahl CM"],"additional_accession":[]},"is_claimable":false,"name":"Establishing the Kenya National Antivenom Quality Control Laboratory: Preclinical Efficacy Results of Four Antivenoms Against Venoms from the \"Big Five\" Snake Species in Kenya.","description":"Antivenom administration is currently the only therapy for snakebite envenoming. However, in sub-Saharan Africa, inadequate quality control systems have led to deficits in the availability, accessibility, efficacy and safety of regionally available antivenoms, which, in turn, hinder snakebite treatment and management in the region. To address this impediment to snakebite treatment in Kenya, this study aimed to assess the preclinical neutralising potencies of four different antivenoms previously or currently available in Kenya (SAIMR polyvalent, AFRIVEN, PANAF-Premium<sup>TM</sup> and Inoserp<sup>TM</sup>) against key snakes of medical importance in the region, towards establishing a national antivenom quality control laboratory. Venoms were extracted from the Kenyan \"big five\" medically im","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-11T03:12:10.347Z","creation":"2026-07-11T03:09:05.199Z"},"accession":"S-EPMC12945176","cross_references":{"pubmed":["41745771"],"doi":["10.3390/toxins18020106"]}}